Article Text
Abstract
For some time, paediatric neurologists have recognised glucose transporter type 1 (GluT1) deficiency syndrome as a cause of intractable infantile seizures, microcephaly, developmental delay and hypoglycorrhachia in the presence of a normal plasma glucose. It is caused by mutations in the SLC2A1 gene, coding for GluT1, leading to a reduction in the available glucose transporter sites; it responds to the ketogenic diet. Recently, a wider spectrum of seizure syndromes have been associated with functional impairment of glucose transport caused by SLC2A1 mutations. These syndromes include 12% of early-onset absence epilepsy and 1% of genetic generalised epilepsies, where they represent a risk allele contributing to polygenic inheritance. We describe a young man with early-onset absence seizures and paroxysmal exercise-induced dyskinesia. While this syndrome is uncommon, it is recognisable and its diagnosis allows consideration of treatment with the ketogenic diet. We discuss the role of genetic testing in early-onset absence seizures and genetic generalised epilepsy.
- Glucose Transporter Type 1 Deficiency Syndrome
- Epilepsy, Absence
- Epilepsy, Generalised
- Genetic Testing
- Ketogenic Diet
Statistics from Altmetric.com
Linked Articles
- Editors' commentary
Read the full text or download the PDF:
Other content recommended for you
- It is all in the history, or is it?
- Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency
- Unravelling of the paroxysmal dyskinesias
- Long-term follow-up in an open-label trial of triheptanoin in GLUT1 deficiency syndrome: a sustained dramatic effect
- Transition from ketogenic diet to triheptanoin in patients with GLUT1 deficiency syndrome
- Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches
- Investigating adults with early-onset epilepsy and intellectual or physical disability
- Recent advances in the molecular genetics of epilepsy
- Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies
- Neurodegenerative disorders and metabolic disease